Verrica Pharmaceuticals Inc. (VRCA)
After hours:
| Previous close | 6.79 |
| Open | 6.78 |
| Bid | 6.83 x 200 |
| Ask | 6.88 x 400 |
| Day's range | 6.78 - 6.94 |
| 52-week range | 2.86 - 7.76 |
| Volume | |
| Avg. volume | 134,701 |
| Market cap | 290.578M |
| Beta (5Y monthly) | 1.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.48 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
Simply Wall St.Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss
This week we saw the Verrica Pharmaceuticals Inc. ( NASDAQ:VRCA ) share price climb by 11%. But over the last three...
GlobeNewswireVerrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica’s President & Chief Executive Officer, will present at the upcoming 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from April 8-11, 2024. Event details:Date: Tuesday, April 9, 2024Time: 2:15 pm ET Participa
- GlobeNewswire
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
NCE status provides a minimum of five years of regulatory exclusivity The Company’s U.S. patents and pending patent applications related to YCANTH™ are projected to expire between 2034 and 2041, excluding any patent term adjustment or patent term extension WEST CHESTER, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today
